Contact Us  +(1) 855 8KRANE8  info@kraneshares.com
中文

KURE

KraneShares MSCI All China Health Care Index ETF

Download KURE Presentation

Download Fact Sheet

Investment Strategy:

KURE seeks to measure the performance of MSCI China All Shares Health Care 10/40 Index. The Index is a free float adjusted market capitalization weighted index designed to track the equity market performance of Chinese companies engaged in the health care sector. The securities in the Index include all types of publicly issued shares of Chinese issuers, which are listed in Mainland China, Hong Kong and United States. Issuers eligible for inclusion must be classified under the Global Industry Classification Standard as engaged in the healthcare sector. The issuers included in the Underlying Index may include small-cap, mid-cap and large-cap companies.

China Health Care Sector Highlights:

  • China currently has the fastest growing major healthcare market in the world with a five-year compound annual growth rate of 17%, compared to just 4% in the United States, and -2% in Japan1.
  • China is the second largest healthcare market globally with total healthcare expenditure reaching $594 billion in 20151. A number projected to reach $1.1 trillion by 20202.
  • There is still opportunity for considerable growth in China’s healthcare market with per capita health spending at just $420, compared to an average of over $5,800 for the world’s top eight healthcare markets in terms of per capita expenditure3.
  • China’s aging population, rising incomes and increasing urbanization may provide a sustained catalyst for growth in China’s healthcare sector.

KURE features:

  • Exposure to Chinese companies listed in the Mainland, Hong Kong and United States that are involved in the healthcare industry, specifically: patent and generic pharmaceuticals, hospital administration, biotechnology, medical equipment production, healthcare IT, and traditional Chinese medicine.
  • Exposure to companies that benefit from China’s growing middle class and aging population.
  • Access to leading Chinese pharmaceutical companies which have been recipients of favorable policy and market conditions for research and development and the invention of new medicines and devices.

1.) Major healthcare markets defined as top five global markets by the World Health Organization. Data from the World Health Organization as of 12/31/2015 retrieved 01/29/2018

2.) International Trade Association, "2016 Top Markets Report Pharmaceuticals, 2016". Retrieved 01/26/2018.

3.) Data from IMS Market Prognosis, 10/2016

Fund Details

Data as of 04/24/2018
TickerKURE
Primary ExchangeNYSE
CUSIP922908108
ISINUS9229081081
Net Assets$18,444,565
Total Annual Fund Operating Expense 0.79%
Inception Date02/01/2018
Distribution FrequencySemiannually

Fund Documents

Daily Performance

Data as of 04/24/2018
Premium Discount Chart
NAV
Net Asset Value$26.35 
Daily Change 1.79%
Price
Closing Price $0.00 
Daily Change0.00%

Performance History

Distributions
Cumulative %
Data as of: 03/31/2018		 Fund NAVClosing PriceIndex
1 Month8.78%10.69%11.06%
3 Month–––
6 Month–––
Since Inception6.60%8.56%7.46%
Cumulative %
Data as of quarter end: 03/31/2018		 Fund NAVClosing PriceIndex
Since Inception6.60% 8.56%7.46%

The performance data quoted represents past performance. Past performance does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor's shares, when sold or redeemed, may be worth more or less than their original cost and current performance may be lower or higher than the performance quoted.

Top 10 Holdings

Data as of 04/24/2018
Full Holdings .CSV
RankCompany Name% of Net AssetsTickerShares HeldMarket Value($)
1
CASH
10.97%–2,022,9792,022,979
2
CSPC PHARMACEUTICAL GROUP
10.97%1093 HK780,0002,022,824
3
JIANGSU HENGRUI MEDICINE
9.16%–125,8411,690,259
4
SINO BIOPHARMACEUTICAL
7.24%1177 HK658,0001,334,959
5
SINOPHARM GROUP CO-H
4.52%1099 HK190,400833,475
6
KANGMEI PHARMACEUTICAL CO
4.18%–224,000770,014
7
SHANGHAI FOSUN PHARMACEUT
2.79%2196 HK89,500514,968
8
CHINA MEDICAL SYSTEM HOLD
2.71%867 HK210,000498,844
9
SHANGHAI FOSUN PHARMACEUT
2.69%–79,483496,446
10
WUXI BIOLOGICS CAYMAN INC
2.45%2269 HK49,000452,099

Holdings are subject to change.

Related Content:

Topics

©2018 Krane Funds Advisors, LLC
1270 Ave of the Americas, Suite 2217, New York, NY 10020

Carefully consider the Funds' investment objectives, risk factors, charges and expenses before investing. This and additional information can be found in the Funds' full & summary prospectus, which may be obtained here: KWEB, KBA, OBOR, KGRN, KARS, KURE, KEMQ, KCNY, KFYP, KEMP Read the prospectus carefully before investing.

Investing involves risk, including possible loss of principal. There can be no assurance that a Fund will achieve its stated objectives. ETF shares are not redeemable with the issuing fund other than in large Creation Unit aggregations. Instead, investors must buy or sell ETF Shares in the secondary market with the assistance of a stockbroker. In doing so, the investor may incur brokerage commissions and may pay more than net asset value when buying and receive less than net asset value when selling. The NAV of the Fund’s shares is calculated each day the national securities exchanges are open for trading as of the close of regular trading on the New York Stock Exchange (“NYSE”), normally 4:00 p.m. Eastern time (the “NAV Calculation Time”). Shares are bought and sold at market price (closing price) not NAV. Market price returns are based on the midpoint of the bid/ask spread at 4:00 pm Eastern Time (when NAV is normally determined).

The Funds are subject to political, social or economic instability within China which may cause decline in value. Fluctuations in currency of foreign countries may have an adverse effect to domestic currency values. Emerging markets involve heightened risk related to the same factors as well as increase volatility and lower trading volume.

Narrowly focused investments typically exhibit higher volatility. Internet companies are subject to rapid changes in technology, worldwide competition, rapid obsolescence of products and services, loss of patent protections, evolving industry standards and frequent new product productions. Such changes may have an adverse impact on performance. Technology companies may be subject to severe competition and rapid obsolescence. The KraneShares CSI China Internet ETF, the KraneShares MSCI One Belt One Road ETF, the KraneShares Zacks New China ETF, the KraneShares Emerging Markets Consumer Technology ETF, the KraneShares MSCI China Environment ETF, the KraneShares Electric Vechicles and Future Mobility Index ETF, and the KraneShares MSCI All China Health Care Index ETF are non-diversified.

The ability of the KraneShares Bosera MSCI China A ETF, the KraneShares FTSE Emerging Markets Plus ETF, the KraneShares MSCI One Belt One Road ETF, the KraneShares Emerging Markets Consumer Technology ETF, the KraneShares Electric Vechicles and Future Mobility Index ETF, and the KraneShares MSCI All China Health Care Index ETF to achieve their respective investment objectives is dependent, in part, on the continuous availability of A Shares and the ability to obtain, if necessary, additional A Shares quota. If a Fund is unable to obtain sufficient exposure to limited availability of A Share quota, the Fund could seek exposure to the component securities of the Underlying Index by investment in other types of securities. The funds may in invest in derivatives, which are often more volatile than other investments and may magnify the Funds’ gains or losses.

The KraneShares E Fund China Commercial Paper ETF is subject to interest rate risk, which is the chance that bonds will decline in value as interest rates rise. The components of the securities held by the Fund will be rated by Chinese credit rating agencies, which may use different criteria and methodology than U.S. entities or international credit rating agencies. The Fund may invest in high yield and unrated securities, whose prices are generally more sensitive to adverse economic changes and consequently more volatile. The Fund is subject to industry concentration risk and is non-diversified. Narrowly focused investments typically exhibit higher volatility.

The KraneShares MSCI All China Health Care Index ETF invests primarily in the health care industry. The profitability of companies in the healthcare sector may be affected by government regulations and government healthcare programs, government reimbursement for medical expenses, increases or decreases in the cost of medical products and services, limited product lines, increased emphasis on the delivery of healthcare through outpatient services and product liability claims. Many healthcare companies are heavily dependent on patent protection, which may be time consuming and costly, and the expiration of a company’s patent may adversely affect that company’s profitability. Healthcare companies are subject to competitive forces that may result in pricing pressure, including price discounting, and may be thinly capitalized and susceptible to product obsolescence. Many new products in the healthcare sector require significant research and development and may be subject to regulatory approvals, which may be time consuming and costly and with no guarantee that the product will come to market.

Indices are unmanaged and do not include the effect of fees. One cannot invest directly in an index.

The KraneShares ETFs are distributed by SEI Investments Distribution Company (SIDCO), 1 Freedom Valley Drive, Oaks, PA 19456, which is not affiliated with Krane Funds Advisors, LLC, the Investment Adviser for the Fund.

Privacy Policy